Phathom Pharmaceuticals Inc

$9.14
(as of Jun 9, 9:30 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Phathom Pharmaceuticals Inc

Stock Price
$9.14
Ticker Symbol
PHAT
Exchange
NASDAQ

Industry Information for Phathom Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Phathom Pharmaceuticals Inc

Website
https://www.phathompharma.com
Country
USA
Full Time Employees
427

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Fundamentals for Phathom Pharmaceuticals Inc

Market Capitalization
$622,741,760
EBITDA
$-285,617,984
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-5.18
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
69,814,096
Percent Owned by Insiders
4.22%
Percent Owned by Institutions
85.75%
52-Week High
52-Week Low

Technical Indicators for Phathom Pharmaceuticals Inc

50-Day Moving Average
200-Day Moving Average
RSI
82.92
ATR
0.95

Analyst Ratings for Phathom Pharmaceuticals Inc

Strong Buy
6
Buy
2
Hold
1
Sell
0
Strong Sell
0

News About Phathom Pharmaceuticals Inc

Jun 6, 2025, 12:27 PM EST
[Going Up] See more.
Jun 6, 2025, 12:27 PM EST
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. See more.
May 1, 2025, 4:15 PM EST
FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. See more.
May 1, 2025, 7:00 AM EST
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwinds Strategic cost reductions and executive leadership changes implemented to support sustainablerevenue growth and achieve profit from operations, excluding stock-based compensation,in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. See more.